# US 2011/0300119 A1 · Methods of enriching and using regulatory t cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0300119 A1
- Document ID: US20110300119A1
- Status: Published application
- Kind: A1
- Application number: 13/060,043
- Filed: 2009-08-21
- Published: 2011-12-08
- Earliest claimed: 2008-08-21
- Assignees: The United States of America, as represented by the Secretary, Department of Health and
- Inventors: Dat Tran; Ethan M. Shevach
- Web page: https://patentgrep.com/patent/US20110300119A1

## CPC

- C12N 5/0636: {T lymphocytes}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K 2035/122: {for inducing tolerance or supression of immune responses}
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/23: Interleukins [IL]
- C12N 2501/51: B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are methods of isolating and using a population of FOXP3+ regulatory T cells in a variety of preventative and therapeutic approaches to autoimmune diseases, graft-versus-host disease and transplant rejection.

## Claims

### Claim 1

A method of making an isolated population of FOXP3+ regulatory T cells, comprising
obtaining a biological sample containing T-cells from a mammal; and,
contacting the biological sample with a labeled antibody or antibody fragment that specifically recognizes a cell surface protein selected from the group consisting of latency-associated peptide (LAP), IL-1 receptor type I (CD121a), IL-1 receptor type II (CD121b) and GARP (LRRC32) to identify and isolate FOXP3+ T cells from T cells in the biological sample that are FOXP3−.

### Claim 2

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the antibody label is at least one of biotin, avidin, streptavidin, fluorochromes, including phycobiliproteins, including phycoerythrin and allophycocyanins, fluorescein and Texas red.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antibody label is attached to the antibody by a linker which can be cleaved or separated or subject to hydrolysis by contact with an enzyme under physiological conditions.

### Claim at position 5

6-8. (canceled)

### Claim 9 (depends on 2)

The method of claim 2, wherein the isolating comprises sorting the T cells according to the amount of labeled antibody bound to them, wherein cells having bound antibody are identified as FOXP3+ regulatory T cells and isolated from cells lacking antibody bound to them.

### Claim 10 (depends on 1)

The method of claim 1, wherein the isolating comprises an immunological selection technique selected from the group consisting of flow cytometry, fluorescence-activated cell sorting (FACS), and magnetic bead based isolation technique.

### Claim 11

(canceled)

### Claim 12 (depends on 9)

The method of claim 9, wherein the sorting is magnetic selection conducted using an antibody or antibody fragment conjugated to a magnetic particle.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the isolated T cells are greater than 70% FOXP3+ cells.

### Claim at position 12

15-17. (canceled)

### Claim 18 (depends on 1)

The method of claim 1, wherein the isolated T cells are highly anergic.

### Claim 19 (depends on 1)

The method of claim 1, wherein the isolated T cells are immunosuppressive in vitro.

### Claim 20 (depends on 1)

The method of claim 1, wherein the isolated T cells are immunosuppressive in vivo.

### Claim 21

(canceled)

### Claim 22 (depends on 20)

The method of claim 20, wherein the blood is selected from peripheral blood, spleen blood and cord blood.

### Claim 23 (depends on 1)

The method of claim 1, wherein the biological sample comprises lymph node tissue.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The method of claim 1, further comprising contacting the biological sample, or a portion thereof, with a chemical that induces the expansion, proliferation, activation, or growth of T cells, or specific populations of T cells.

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28 (depends on 1)

The method of claim 1, wherein the biological sample or a portion thereof is contacted with a cell that induces the expansion, proliferation, activation, or growth of T cells or specific populations of T cells.

### Claim 29 (depends on 27)

The method of claim 27, wherein the cell is a stromal cell.

### Claim 30 (depends on 27)

The method of claim 27, wherein the cell is one of a donor-specific antigen presenting cells, and antigen presenting cell from a source separate from the donor.

### Claim at position 26

31-37. (canceled)

### Claim 38 (depends on 1)

The method of claim 1, further comprising suspending the isolated FOXP3+ T cells in a physiologically-acceptable medium and administering the suspension to a mammal for therapeutic purposes.

### Claim 39

(canceled)

### Claim 40

A method of analyzing a biological sample from a mammal for the presence of FOXP3+ regulatory T cells, comprising:
contacting the biological sample with a labeled antibody that specifically recognizes a cell surface protein selected from the group consisting of latency-associated peptide (LAP), IL-1 receptor type I (CD121a), IL-1 receptor type II (CD121b) and GARP (LRRC32); and,
quantitating the presence of FOXP3+ T regulatory cells in the sample, wherein the presence of the cell surface protein as compared to a control sample lacking FOXP3+ cells is indicative of the presence of regulatory T cells in the test sample.

### Claim at position 30

41-66. (canceled)

### Claim 67

A method of treating or preventing a disorder selected from the group consisting of an autoimmune disorder, graft-versus-host disease, and transplant rejection in a mammal comprising administering a population of isolated FOXP3+ T-cells to a mammal selected from the group consisting of a mammal suffering an autoimmune disorder or graft-versus-host disease, a donor of a transplant tissue, and a recipient of a transplant tissue.

### Claim 68 (depends on 67)

The method of claim 67, wherein the disorder is an autoimmune disorder selected from the group consisting of systemic lupus erythematosus (SLE), rheumatoid arthritis, type 1 diabetes, multiple sclerosis (MS), aplastic anemia, and idiopathic thrombocytopenic purpura.

### Claim at position 33

69-74. (canceled)
